ClinicalTrials.gg
CompletedNCT04875195Updated Oct 27, 2026Results posted

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

A Phase 2 interventional study of Pembrolizumab in Hodgkin's Lymphoma and Primary Mediastinal Large B-cell Lymphoma (PMBCL), sponsored by Merck Sharp & Dohme LLC. Completed at 27 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Updated Oct 27, 2026Posted results revisedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing pembrolizumab in Hodgkin Disease — 13 open to participants now, 21 under way, 2 of them phase 3. pembrolizumab · Hodgkin Disease.

Enrollment
10th of 30
66 · median 34
Started
2021
the only one that year
Phase 2
22 of 30
11 open now
Registered
15th of 30
by date
Lead sponsor
5 of 30
Merck Sharp & Dohme LLC

Among the 30 studies testing pembrolizumab in Hodgkin Disease, this one is the 10th largest by enrollment, is the only one that started in 2021, is one of 22 in phase 2, and was the 15th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

13 of the 30 studies testing pembrolizumab in Hodgkin Disease are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing pembrolizumab in Hodgkin Disease, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the objective response rate (ORR), by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in participants treated with pembrolizumab every six weeks (Q6W).

03

Conditions studied

  • Hodgkin's Lymphoma
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Browse trials for

Keywords

  • PD1
  • PD-1
  • PDL1
  • PD-L1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a confirmed diagnosis of cHL or PMBCL, according to the World Health Organization (WHO) classification [Swerdlow, S. H., et al 2008].
  • Has radiographically measurable cHL or PMBCL disease as per Lugano classification with at least 1 nodal lesion (which has not been previously radiated) that is >15 mm in long axis, regardless of the length of the short axis, and/or extranodal lesion of >10 mm in long and short axis.

PMBCL-Specific Disease Characteristics:

  • Have PMBCL and:
  • Have relapsed after auto-stem cell transplant (SCT) or have failed to achieve a CR or PR within 60 days of auto-SCT. Participants may have received intervening therapy after auto-SCT for relapsed or refractory disease, in which case they must have relapsed after or be refractory to their last treatment.

OR

- For participants who are ineligible for auto-SCT, have received at least ≥2 and have failed to respond to or relapsed after their last line of treatment. At least 1 of the prior lines of therapy must contain a rituximab-based regimen.

Note: Participants should not need urgent cytoreductive therapy.

  • Relapsed Disease: disease progression after achieving an overall response of PR or CR in response to the most recent therapy
  • Refractory Disease: failure to achieve CR or PR to the most recent therapy.

cHL-Specific Disease Characteristics:

  • Have relapsed or refractory cHL and:
  • Have relapsed during their last cHL regimen after receiving at least 2 cycles of therapy or within 12 months after completing the last regimen for cHL.

OR

  • Have received at least ≥1 line of prior multiagent therapy with/without brentuximab vedotin (excluding radiation) or auto-SCT for cHL and have failed to respond to or relapsed after their last line of treatment.

    • Relapsed Disease: disease progression after achieving an overall response of PR or CR to the most recent therapy.
    • Refractory Disease: failure to achieve CR or PR to the most recent therapy.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
  • Is not a woman of child bearing potential (). OR
  • Is a WOCBP and using a method that is highly effective (with a failure rate of \<1% per year), or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), for at least 120 days after the last dose of study intervention.
  • Submit an evaluable core lymph node for biomarker analysis from an archival (>60 days) or newly obtained (within 30 days) core or incisional biopsy at Screening which was not previously irradiated. Note: If no archival tissue is available, 2 new fresh core needle samples are required.
  • Have an (ECOG) performance status of 0 to 1.
  • >3 months.
  • Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Has undergone solid organ transplant at any time, or prior hematopoietic SCT within the last 5 years
  • Has (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (\<6 months prior to enrollment), myocardial infarction (\<6 months prior to enrollment), unstable angina, congestive heart failure ( Classification Class ≥II), or serious cardiac arrhythmia requiring medication
  • Has pericardial effusion or clinically significant pleural effusion
  • Has a history of a second , unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. Note: The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, in situ cervical cancer, or other in situ cancers
  • Is receiving systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) \<3 days prior to the first dose of study intervention. Note: Participants who receive daily steroid replacement therapy are an exception
  • Has received prior monoclonal antibody within 4 weeks prior to first dose of study intervention or has not recovered (i.e., ≤Grade 1 or at baseline) from adverse event (AEs) due to agents administered more than 4 weeks earlier
  • Has received prior therapy with an anti-programmed cell death 1 protein (), anti-programmed cell death ligand 1 (PD-L1), or anti-programmed cell death ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137)
  • Has received prior chimeric antigen receptor T-cell (CAR-T) therapy
  • Has received prior systemic anticancer therapy, or radiotherapy, including agents within 4 weeks prior to the first dose of study intervention. Note: If the participant had a major operation, the participant must have recovered adequately from the procedure and/or any complications from the operation before starting study intervention
  • Has received prior radiotherapy within 2 weeks of start of study intervention or have had a history of radiation pneumonitis. Participants must have recovered from all radiation-related toxicities, and not require corticosteroids
  • Has received a live or within 30 days before the first dose of study drug
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to the first dose of study medication
  • Has known active central nervous system (CNS) lymphoma involvement or active CNS involvement by lymphoma
  • Has severe (≥Grade 3) to pembrolizumab and/or any of its
  • Has an active disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
  • Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • Has an active infection requiring systemic therapy
  • Has a known history of (HIV) infection. No HIV testing is required unless mandated by local health authority
  • Has a known history of (defined as hepatitis B surface antigen (HBsAg) reactive) or known active virus infection
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Arm 1

    Pembrolizumab (MK-3475), 400 mg, Q6W, intravenous (IV) infusion, Day 1 then Q6W up to 18 doses.

    Biological: Pembrolizumab

Interventions

  • BiologicalPembrolizumab

    Pembrolizumab, 400 mg, Q6W, intravenous (IV) infusion.

    Also known as: MK-3475, SCH 900475, KEYTRUDA®

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Per Lugano Classification as Assessed by Investigator

    ORR is defined as the percentage of the participants who had complete response (CR) or partial response (PR) and was evaluated using computed tomography (CT) and metabolic imaging (fluorodeoxyglucose- positron emission tomography (FDG-PET)). CR is complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. PR is partial metabolic (moderate/high FDG uptake) and radiologic response (≥50% decrease in sum of product diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \>50% in length beyond normal). The percentage of participants treated with pembrolizumab Q6W, by cohort, rrcHL and rrPMBCL, who experienced CR or PR as assessed by investigator is presented.

    Time frame: Up to approximately 30 months

Secondary outcomes

  1. ORR Per Lugano Classification as Assessed by Blinded Independent Central Review (BICR)

    ORR is defined as the percentage of the participants who had complete response (CR) or partial response (PR) and was evaluated using computed tomography (CT) and metabolic imaging (fluorodeoxyglucose-positron emission tomography (FDG-PET)). CR is complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. PR is partial metabolic (moderate/high FDG uptake) and radiologic response (≥50% decrease in sum of product diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \>50% in length beyond normal). The percentage of participants treated with pembrolizumab Q6W, by cohort, rrcHL and rrPMBCL, who experienced CR or PR as assessed by BICR is presented.

    Time frame: Up to approximately 30 months

  2. Duration of Response (DOR) Per Lugano Classification as Assessed by Investigator

    For participants who demonstrate a CR or PR, DOR is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first. Participants were evaluated using CT and metabolic imaging (FDG-PET). CR is complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. PR is partial metabolic (moderate/high FDG uptake) and radiologic response (≥50% decrease in sum of product diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \>50% in length beyond normal). DOR as assessed by investigator is presented among participants who demonstrated CR or PR.

    Time frame: Up to approximately 51 months

  3. DOR Per Lugano Classification as Assessed by BICR

    For participants who demonstrate a CR or PR, DOR is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first. Participants were evaluated using CT and metabolic imaging (FDG-PET). CR is complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. PR is partial metabolic (moderate/high FDG uptake) and radiologic response (≥50% decrease in sum of product diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \>50% in length beyond normal). DOR as assessed by BICR is presented among participants who demonstrated CR or PR.

    Time frame: Up to approximately 51 months

  4. Area Under the Curve (AUC) Early Cycle of Pembrolizumab

    AUC was defined as a measure of pembrolizumab exposure that was calculated as the product of serum drug concentration and time. Blood samples were collected to determine the AUC of pembrolizumab during Cycle 1 (early cycle). A cycle was 6 weeks.

    Time frame: Predose on Day 1 and Day 42 of Cycle 1 (cycle length=6 weeks)

  5. Area Under the Curve (AUC) Steady State of Pembrolizumab

    AUC was defined as a measure of pembrolizumab exposure that was calculated as the product of serum drug concentration and time. Blood samples were collected to determine the AUC of pembrolizumab during Cycle 4 (steady state). A cycle was 6 weeks.

    Time frame: Predose on Day 1 and Day 42 of Cycle 4 (cycle length=6 weeks)

  6. Maximum Serum Concentration (Cmax) Early Cycle of Pembrolizumab

    Cmax is defined as the maximum serum drug concentration. Blood samples were collected to determine the Cmax of pembrolizumab during Cycle 1 (early cycle).

    Time frame: Predose on Day 1 of Cycle 1 and end of infusion on Day 1 of Cycle 1 (cycle length = 6 weeks)

  7. Maximum Serum Concentration (Cmax) Steady State of Pembrolizumab

    Cmax is defined as the maximum serum drug concentration. Blood samples were collected to determine the Cmax of pembrolizumab during Cycle 4 (steady state).

    Time frame: Predose on Day 1 of Cycle 4, and end of infusion on Day 1 of Cycle 4 (cycle length = 6 weeks)

  8. Trough Serum Concentration (Ctrough) Early Cycle of Pembrolizumab

    Ctrough is defined as the lowest serum drug concentration at the end of dosing interval. Blood samples were collected to determine the Ctrough of pembrolizumab during Cycle 1 (early cycle).

    Time frame: Predose on Day 1 of Cycle 1 and Day 42 of Cycle 1 (cycle length = 6 weeks)

  9. Trough Serum Concentration (Ctrough) Steady State of Pembrolizumab

    Ctrough is defined as the lowest serum drug concentration at the end of dosing interval. Blood samples were collected to determine the Ctrough of pembrolizumab during Cycle 4 (steady state).

    Time frame: Predose on Day 1 of Cycle 1 and Day 42 of Cycle 4 (cycle length = 6 weeks)

  10. Antidrug Antibody Levels (ADA) for Pembrolizumab

    Blood samples were collected and assayed for anti-pembrolizumab antibodies presence using a validated electrochemiluminescence immunoassay. Negative ADA refers to all pre-treatment and postdose samples negative in the assay for antibodies against pembrolizumab and the concentration of pembrolizumab in the last postdose sample below the drug tolerance level. Treatment emergent positive was defined as pre-treatment sample negative and at least one postdose sample positive in the assay or pre-treatment and postdose sample positive with an increase in titer (≥2 fold of baseline). Non-treatment emergent positive was defined as pre-treatment sample positive and postdose sample negative or pre-treatment and postdose sample positive with a postdose titer \<2 fold of baseline. Neutralizing positive was defined as at least 1 of the ADA positive samples test positive in the neutralizing assay.

    Time frame: Predose 0-4 hours on Cycle1 Day1, Cycle2 Day1, Cycle4 Day1, Cycle5 Day1, Cycle7 Day1, Cycle9 Day1, Cycle13 Day1, Cycle17 Day1 and end of infusion on Cycle1 Day1, Cycle4 Day1 and anytime on Cycle1 Day22 and Cycle4 Day22 (cycle length = 6 weeks)

  11. Number of Participants Who Experienced an Adverse Event (AE)

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to approximately 51 months

  12. Number of Participants Who Discontinued Study Treatment Due to AE

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to approximately 25 months

07

Results

Posted Feb 10, 2025

Participant flow

Participant flow — Overall Study
MilestoneRelapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL)Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)
Started606
Completed00
Not completed606
Withdrew: Death153
Withdrew: Withdrawal by subject21
Withdrew: Discontinued by sponsor432

Outcome measures

PrimaryObjective Response Rate (ORR) Per Lugano Classification as Assessed by Investigator

ORR is defined as the percentage of the participants who had complete response (CR) or partial response (PR) and was evaluated using computed tomography (CT) and metabolic imaging (fluorodeoxyglucose- positron emission tomography (FDG-PET)). CR is complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. PR is partial metabolic (moderate/high FDG uptake) and radiologic response (≥50% decrease in sum of product diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \>50% in length beyond normal). The percentage of participants treated with pembrolizumab Q6W, by cohort, rrcHL and rrPMBCL, who experienced CR or PR as assessed by investigator is presented.

Time frame:
Up to approximately 30 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Per Lugano Classification as Assessed by Investigator
Percentage of ParticipantsRelapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL)Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)
Objective Response Rate (ORR) Per Lugano Classification as Assessed by Investigator66.7 (53.3 to 78.3)50.0 (11.8 to 88.2)
SecondaryORR Per Lugano Classification as Assessed by Blinded Independent Central Review (BICR)

ORR is defined as the percentage of the participants who had complete response (CR) or partial response (PR) and was evaluated using computed tomography (CT) and metabolic imaging (fluorodeoxyglucose-positron emission tomography (FDG-PET)). CR is complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. PR is partial metabolic (moderate/high FDG uptake) and radiologic response (≥50% decrease in sum of product diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \>50% in length beyond normal). The percentage of participants treated with pembrolizumab Q6W, by cohort, rrcHL and rrPMBCL, who experienced CR or PR as assessed by BICR is presented.

Time frame:
Up to approximately 30 months
Reported as:
Number · Percentage of Participants
ORR Per Lugano Classification as Assessed by Blinded Independent Central Review (BICR)
Percentage of ParticipantsRelapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL)Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)
ORR Per Lugano Classification as Assessed by Blinded Independent Central Review (BICR)70.0 (56.8 to 81.2)66.7 (22.3 to 95.7)
SecondaryDuration of Response (DOR) Per Lugano Classification as Assessed by Investigator

For participants who demonstrate a CR or PR, DOR is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first. Participants were evaluated using CT and metabolic imaging (FDG-PET). CR is complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. PR is partial metabolic (moderate/high FDG uptake) and radiologic response (≥50% decrease in sum of product diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \>50% in length beyond normal). DOR as assessed by investigator is presented among participants who demonstrated CR or PR.

Time frame:
Up to approximately 51 months
Reported as:
Median · Months
Duration of Response (DOR) Per Lugano Classification as Assessed by Investigator
MonthsRelapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL)Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)
Duration of Response (DOR) Per Lugano Classification as Assessed by Investigator15.2 (5.6 to 25.7)9.7 (2.6 to NA)
SecondaryDOR Per Lugano Classification as Assessed by BICR

For participants who demonstrate a CR or PR, DOR is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first. Participants were evaluated using CT and metabolic imaging (FDG-PET). CR is complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. PR is partial metabolic (moderate/high FDG uptake) and radiologic response (≥50% decrease in sum of product diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \>50% in length beyond normal). DOR as assessed by BICR is presented among participants who demonstrated CR or PR.

Time frame:
Up to approximately 51 months
Reported as:
Median · Months
DOR Per Lugano Classification as Assessed by BICR
MonthsRelapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL)Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)
DOR Per Lugano Classification as Assessed by BICR28.5 (28.1 to 30.4)NA (NA to NA)
SecondaryArea Under the Curve (AUC) Early Cycle of Pembrolizumab

AUC was defined as a measure of pembrolizumab exposure that was calculated as the product of serum drug concentration and time. Blood samples were collected to determine the AUC of pembrolizumab during Cycle 1 (early cycle). A cycle was 6 weeks.

Time frame:
Predose on Day 1 and Day 42 of Cycle 1 (cycle length=6 weeks)
Reported as:
Geometric mean · day*µg/mL
Area Under the Curve (AUC) Early Cycle of Pembrolizumab
day*µg/mLrrcHL or rrPMBCL
Area Under the Curve (AUC) Early Cycle of PembrolizumabNA (NA to NA)
SecondaryArea Under the Curve (AUC) Steady State of Pembrolizumab

AUC was defined as a measure of pembrolizumab exposure that was calculated as the product of serum drug concentration and time. Blood samples were collected to determine the AUC of pembrolizumab during Cycle 4 (steady state). A cycle was 6 weeks.

Time frame:
Predose on Day 1 and Day 42 of Cycle 4 (cycle length=6 weeks)
Reported as:
Geometric mean · day*µg/mL
Area Under the Curve (AUC) Steady State of Pembrolizumab
day*µg/mLrrcHL or rrPMBCL
Area Under the Curve (AUC) Steady State of PembrolizumabNA (NA to NA)
SecondaryMaximum Serum Concentration (Cmax) Early Cycle of Pembrolizumab

Cmax is defined as the maximum serum drug concentration. Blood samples were collected to determine the Cmax of pembrolizumab during Cycle 1 (early cycle).

Time frame:
Predose on Day 1 of Cycle 1 and end of infusion on Day 1 of Cycle 1 (cycle length = 6 weeks)
Reported as:
Geometric mean · μg/ml
Maximum Serum Concentration (Cmax) Early Cycle of Pembrolizumab
μg/mlrrcHL or rrPMBCL
Maximum Serum Concentration (Cmax) Early Cycle of Pembrolizumab127.5 (120.0 to 135.4)
SecondaryMaximum Serum Concentration (Cmax) Steady State of Pembrolizumab

Cmax is defined as the maximum serum drug concentration. Blood samples were collected to determine the Cmax of pembrolizumab during Cycle 4 (steady state).

Time frame:
Predose on Day 1 of Cycle 4, and end of infusion on Day 1 of Cycle 4 (cycle length = 6 weeks)
Reported as:
Geometric mean · μg/ml
Maximum Serum Concentration (Cmax) Steady State of Pembrolizumab
μg/mlrrcHL or rrPMBCL
Maximum Serum Concentration (Cmax) Steady State of Pembrolizumab154.8 (141.5 to 169.4)
SecondaryTrough Serum Concentration (Ctrough) Early Cycle of Pembrolizumab

Ctrough is defined as the lowest serum drug concentration at the end of dosing interval. Blood samples were collected to determine the Ctrough of pembrolizumab during Cycle 1 (early cycle).

Time frame:
Predose on Day 1 of Cycle 1 and Day 42 of Cycle 1 (cycle length = 6 weeks)
Reported as:
Geometric mean · μg/ml
Trough Serum Concentration (Ctrough) Early Cycle of Pembrolizumab
μg/mlrrcHL or rrPMBCL
Trough Serum Concentration (Ctrough) Early Cycle of Pembrolizumab17.9 (16.3 to 19.7)
SecondaryTrough Serum Concentration (Ctrough) Steady State of Pembrolizumab

Ctrough is defined as the lowest serum drug concentration at the end of dosing interval. Blood samples were collected to determine the Ctrough of pembrolizumab during Cycle 4 (steady state).

Time frame:
Predose on Day 1 of Cycle 1 and Day 42 of Cycle 4 (cycle length = 6 weeks)
Reported as:
Geometric mean · μg/ml
Trough Serum Concentration (Ctrough) Steady State of Pembrolizumab
μg/mlrrcHL or rrPMBCL
Trough Serum Concentration (Ctrough) Steady State of Pembrolizumab33.8 (29.9 to 38.4)
SecondaryAntidrug Antibody Levels (ADA) for Pembrolizumab

Blood samples were collected and assayed for anti-pembrolizumab antibodies presence using a validated electrochemiluminescence immunoassay. Negative ADA refers to all pre-treatment and postdose samples negative in the assay for antibodies against pembrolizumab and the concentration of pembrolizumab in the last postdose sample below the drug tolerance level. Treatment emergent positive was defined as pre-treatment sample negative and at least one postdose sample positive in the assay or pre-treatment and postdose sample positive with an increase in titer (≥2 fold of baseline). Non-treatment emergent positive was defined as pre-treatment sample positive and postdose sample negative or pre-treatment and postdose sample positive with a postdose titer \<2 fold of baseline. Neutralizing positive was defined as at least 1 of the ADA positive samples test positive in the neutralizing assay.

Time frame:
Predose 0-4 hours on Cycle1 Day1, Cycle2 Day1, Cycle4 Day1, Cycle5 Day1, Cycle7 Day1, Cycle9 Day1, Cycle13 Day1, Cycle17 Day1 and end of infusion on Cycle1 Day1, Cycle4 Day1 and anytime on Cycle1 Day22 and Cycle4 Day22 (cycle length = 6 weeks)
Reported as:
Count of participants · Participants
Antidrug Antibody Levels (ADA) for Pembrolizumab
ParticipantsrrcHL or rrPMBCL
Negative62
Treatment emergent positive1
Non-Treatment emergent positive1
Neutralizing positive0
SecondaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to approximately 51 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsRelapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL)Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)
Number of Participants Who Experienced an Adverse Event (AE)484
SecondaryNumber of Participants Who Discontinued Study Treatment Due to AE

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

Time frame:
Up to approximately 25 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to AE
ParticipantsRelapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL)Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)
Number of Participants Who Discontinued Study Treatment Due to AE20

Adverse events

Collected over All-cause mortality and adverse events up to approximately 51 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
rrcHL15/60 (25%)6/60 (10%)37/60 (61.7%)
rrPMBCL3/6 (50%)0/6 (0%)4/6 (66.7%)
Most frequent serious events
Most frequent serious events
EventrrcHLrrPMBCL
Febrile neutropeniaBlood and lymphatic system disorders1/600/6
Gastric stenosisGastrointestinal disorders1/600/6
Haemophagocytic lymphohistiocytosisImmune system disorders1/600/6
PeritonitisInfections and infestations1/600/6
PneumoniaInfections and infestations1/600/6
Urinary tract infectionInfections and infestations1/600/6
HypercalcaemiaMetabolism and nutrition disorders1/600/6
DepressionPsychiatric disorders1/600/6
Most frequent other events
Showing 10 of 25
Most frequent other events
EventrrcHLrrPMBCL
COVID-19Infections and infestations13/600/6
Upper respiratory tract infectionInfections and infestations13/600/6
NeutropeniaBlood and lymphatic system disorders4/601/6
Atrial fibrillationCardiac disorders0/601/6
TachycardiaCardiac disorders0/601/6
HypothyroidismEndocrine disorders8/601/6
Abdominal painGastrointestinal disorders5/601/6
FatigueGeneral disorders1/601/6
Peripheral swellingGeneral disorders0/601/6
PyrexiaGeneral disorders2/601/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL)Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)Total
Mean37.7 ± 16.232.5 ± 8.637.3 ± 15.7
Sex: Female, Male
Sex: Female, Male(Participants)Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL)Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)Total
Female31435
Male29231
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL)Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)Total
Hispanic or Latino606
Not Hispanic or Latino50656
Unknown or Not Reported404
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL)Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)Total
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American505
White49554
More than one race303
Unknown or Not Reported303
08

Study locations

27 sites
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site
    Torrance, California 90502, United States
  • Tulane Medical Center ( Site 0110)
    New Orleans, Louisiana 70112, United States
  • Anne Arundel Medical Center-Anne Arundel Oncology and Hematology ( Site 0125)
    Annapolis, Maryland 21401, United States
  • Hospital Erasto Gaertner ( Site 1703)
    Curitiba, Paraná 81520-060, Brazil
  • Fundação Pio XII - Hospital de Câncer de Barretos ( Site 1701)
    Barretos, São Paulo 14784-400, Brazil
  • Cross Cancer Institute ( Site 0207)
    Edmonton, Alberta T6G 1Z2, Canada
  • Fakultni nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0302)
    Brno, Brno-mesto 625 00, Czechia
  • Fakultni nemocnice Kralovske Vinohrady-Interni hematologicka klinika ( Site 0303)
    Prague, Praha 10 100 34, Czechia
  • Fakultni nemocnice Hradec Kralove-IV. interni hematologicka klinika ( Site 0304)
    Hradec Králové, 500 05, Czechia
  • Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand ( Site 0401)
    Dijon, Cote-d Or 21000, France
  • Gustave Roussy ( Site 0402)
    Villejuif, Île-de-France Region 94800, France
  • Fondazione IRCCS Policlinico San Matteo ( Site 0509)
    Pavia, Lombardy 27100, Italy
  • Az. Osp. Ospedali Riuniti VILLA SOFIA-CERVELLO-EMATOLOGIA I ( Site 0507)
    Palermo, Sicily 90146, Italy
  • Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 0503)
    Naples, 80131, Italy
  • Szpital Kliniczny im. Przemienienia Panskiego Uniwersytetu M-Oddzial Hematologii i Transplantacji S
    Poznan, Greater Poland Voivodeship 61-848, Poland
  • Pratia MCM Krakow ( Site 0064)
    Krakow, Lesser Poland Voivodeship 30-510, Poland
  • Uniwersyteckie Centrum Kliniczne-Klinika Hematologii i Transplantologii ( Site 0063)
    Gdansk, Pomeranian Voivodeship 80-952, Poland
  • The National Medico-Surgical Center N.I. Pirogov ( Site 0801)
    Moscow, Moscow 105203, Russia
  • Moscow City Clinical Hospital S.P. Botkin ( Site 0803)
    Moscow, Moscow 125284, Russia
  • Almazov National Medical Research Centre ( Site 0807)
    Saint Petersburg, Sankt-Peterburg 197341, Russia
  • Netcare Pretoria East Hospital-Albert Alberts Stem Cell Transplant Centre ( Site 0902)
    Centurion, Gauteng 0044, South Africa
  • Wits Clinical Research ( Site 0904)
    Johannesburg, Gauteng 1864, South Africa
  • Groote Schuur Hospital ( Site 0906)
    Cape Town, Western Cape 7925, South Africa
  • Ege University Medicine of Faculty ( Site 1105)
    Bornova, İzmir 35100, Turkey (Türkiye)
  • Ankara University Department of Hematology, Clinical Research Unit ( Site 1101)
    Ankara, 06100, Turkey (Türkiye)
  • CNPE Regional Center of Oncology ( Site 1305)
    Kharkiv, Kharkiv Oblast 61070, Ukraine
  • National Cancer Institute ( Site 1303)
    Kyiv, Kyivska Oblast 03022, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Dec 2023, 30 months.

Results were first posted in Feb 2025, 1 year 1 month after primary completion.

Of 206 phase 2 interventional studies under Hodgkin Disease, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 111. This study's 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2021
First posted
May 6, 2021
StartActual
Jun 7, 2021
Primary completionActual
Dec 14, 2023
CompletionActual
Oct 13, 2025
Results first posted
Feb 10, 2025
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Oct 27, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionObjective Response Rate (ORR) Per Lugano Classification as Assessed by Investigator: how it is measured was reworded
Oct 27, 2026
Secondary outcomes
4 time frame changed, 5 description edited
What changed in the outcomes
  • Time frameDuration of Response (DOR) Per Lugano Classification as Assessed by InvestigatorUp to approximately 54 months → Up to approximately 51 months
  • Time frameDOR Per Lugano Classification as Assessed by BICRUp to approximately 54 months → Up to approximately 51 months
  • Time frameNumber of Participants Who Experienced an Adverse Event (AE)Up to approximately 54 months → Up to approximately 51 months
  • Time frameNumber of Participants Who Discontinued Study Treatment Due to AEUp to approximately 54 months → Up to approximately 25 months
  • DescriptionDOR Per Lugano Classification as Assessed by BICR: how it is measured was reworded
  • DescriptionDuration of Response (DOR) Per Lugano Classification as Assessed by Investigator: how it is measured was reworded
  • DescriptionORR Per Lugano Classification as Assessed by Blinded Independent Central Review (BICR): how it is measured was reworded
  • DescriptionTrough Serum Concentration (Ctrough) Early Cycle of Pembrolizumab: how it is measured was reworded
  • DescriptionTrough Serum Concentration (Ctrough) Steady State of Pembrolizumab: how it is measured was reworded
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Posted results revised
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionObjective Response Rate (ORR) Per Lugano Classification as Assessed by Investigator: how it is measured was reworded
    Secondary outcomes 4 time frame changed, 5 description edited
    What changed in the outcomes
    • Time frameDuration of Response (DOR) Per Lugano Classification as Assessed by InvestigatorUp to approximately 54 months → Up to approximately 51 months
    • Time frameDOR Per Lugano Classification as Assessed by BICRUp to approximately 54 months → Up to approximately 51 months
    • Time frameNumber of Participants Who Experienced an Adverse Event (AE)Up to approximately 54 months → Up to approximately 51 months
    • Time frameNumber of Participants Who Discontinued Study Treatment Due to AEUp to approximately 54 months → Up to approximately 25 months
    • DescriptionDOR Per Lugano Classification as Assessed by BICR: how it is measured was reworded
    • DescriptionDuration of Response (DOR) Per Lugano Classification as Assessed by Investigator: how it is measured was reworded
    • DescriptionORR Per Lugano Classification as Assessed by Blinded Independent Central Review (BICR): how it is measured was reworded
    • DescriptionTrough Serum Concentration (Ctrough) Early Cycle of Pembrolizumab: how it is measured was reworded
    • DescriptionTrough Serum Concentration (Ctrough) Steady State of Pembrolizumab: how it is measured was reworded
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04875195
Responsible party
Sponsor
First posted
May 6, 2021
Start date
Jun 7, 2021
Primary completion
Dec 14, 2023
Completion
Oct 13, 2025
Results posted
Feb 10, 2025
Last update
Oct 27, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion